Argos Therapeutics, Inc. Stock

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 278K 257K 237K 447K 30.63M 454K 3.08M 1.21M 14.99M 1.19M 1.17M 51.63M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.02M 3.71M 3.42M 6.45M 442M 6.55M 44.42M 17.41M 216M 17.22M 16.84M 745M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Argos Therapeutics, Inc.

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
13/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
22/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
22/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
04/12/18	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
REGENERON PHARMACEUTICALS, INC.	-0.67%	+1.37%	+23.89%	-7.04%	68.38B
UCB	+0.55%	+2.92%	+38.08%	+191.76%	51.69B
SAMSUNG BIOLOGICS CO.,LTD.	-3.65%	+34.50%	+34.50%	+34.50%	42.1B
CSL LIMITED	-1.00%	-1.28%	-52.46%	-54.56%	41.11B
BIOGEN INC.	-2.93%	-4.34%	+59.97%	-27.21%	29.52B
MODERNA, INC.	-3.77%	-11.22%	+90.31%	-52.32%	23.6B
INCYTE CORPORATION	-1.36%	+1.24%	+70.42%	+80.67%	23.1B
INNOVENT BIOLOGICS, INC.	-0.38%	+2.33%	+3.95%	+180.95%	20.54B
SWEDISH ORPHAN BIOVITRUM AB	-0.50%	+1.85%	+71.90%	+121.88%	16.53B
Average	-0.97%	-1.76%	+37.84%	+52.07%	31.66B
Weighted average by Cap.	-1.08%	-0.86%	+30.63%	+44.85%

	2016	2017
Net sales	945K 829K 766K 705K 1.33M 91.17M 1.35M 9.16M 3.59M 44.61M 3.55M 3.47M 154M	1.9M 1.66M 1.54M 1.42M 2.67M 183M 2.71M 18.4M 7.21M 89.62M 7.13M 6.98M 309M
Net income	-53.03M -46.48M -42.96M -39.51M -74.55M -5.11B -75.75M -514M -201M -2.5B -199M -195M -8.62B	-40.58M -35.57M -32.88M -30.24M -57.05M -3.91B -57.96M -393M -154M -1.91B -152M -149M -6.6B
Net Debt	-13.11M -11.49M -10.62M -9.77M -18.43M -1.26B -18.73M -127M -49.78M -619M -49.22M -48.15M -2.13B	4.27M 3.74M 3.46M 3.18M 6M 412M 6.1M 41.34M 16.21M 201M 16.02M 15.67M 694M

Argos Therapeutics, Inc. Stock

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news : Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile